...
首页> 外文期刊>Vaccine >Vaccines against respiratory syncytial virus: The time has finally come
【24h】

Vaccines against respiratory syncytial virus: The time has finally come

机译:针对呼吸道合胞病毒的疫苗:时间终于来了

获取原文
获取原文并翻译 | 示例
           

摘要

Respiratory syncytial virus causes a significant public health burden, particularly in very young infants and the frail elderly. The legacy of enhanced RSV disease (ERD) from a whole formalin-inactivated RSV vaccine, and the complex biology of the virus and the neonate have delayed the development of effective vaccines. However, new insights into factors associated with ERD and breakthroughs in understanding the antigenic structure of the fusion (F) glycoprotein have increased optimism that vaccine development is possible. This has led to investment of time and resources by industry, regulatory authorities, governments, and nonprofit organizations to develop the infrastructure needed to make the advanced clinical development of RSV vaccine candidates a reality. Published by Elsevier Ltd.
机译:呼吸道合胞病毒导致大量的公共卫生负担,特别是在非常年轻的婴儿和虚弱的老年人。 增强RSV疾病(ERD)的遗产来自整个福尔马林灭活的RSV疫苗,以及病毒和新生儿的复杂生物学延迟了有效疫苗的发展。 然而,在理解融合(F)糖蛋白的抗原结构具有ERD和突破性相关的因素的新见解增加了疫苗发育的乐观态度增加。 这导致了行业,监管机构,政府和非营利组织的时间和资源投资,以制定所需的基础设施,以使RSV疫苗候选人的先进临床发展成为现实。 elsevier有限公司出版

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号